8-K: KALA BIO Secures $375K Convertible Loan Amidst Financial Strain

KALA BIO, Inc. has secured a convertible loan of up to $375,000 from an individual investor to fund immediate operational needs and seek further investment, while facing ongoing foreclosure threats from Oxford Finance LLC.

Summary

• KALA BIO, Inc. entered into a Convertible Loan Agreement on November 9, 2025, for up to $375,000 with an individual investor.
• The loan will be funded in two tranches: $187,500 by November 10, 2025, and the remaining $187,500 by November 12, 2025.
• The loan bears a simple interest rate of 15% per annum, payable monthly starting December 2025.
• The principal is due on the first anniversary of receipt, with an option for a one-year extension.
• The Lender has the right to convert the loan into common stock or receive cash repayment upon a Liquidity Event (M&A or public offering).
• Proceeds are strictly for negotiating an additional investment transaction with the Lender and preparing the Q3 2025 Quarterly Report on Form 10-Q.
• The Company is under an exclusivity agreement with the Lender for investment transactions until November 17, 2025.
• Oxford Finance LLC, a previous lender, had intended to foreclose on KALA BIO's assets and swept its cash, but paused foreclosure on November 3, 2025, allowing $125,000 for immediate needs.
• KALA BIO's ability to continue operations and explore strategic options (sale, merger, additional financing, potential R&D resumption) is contingent on securing further financing.
• If additional financing is not secured, Oxford Finance LLC is expected to resume foreclosure efforts.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, having faced foreclosure and cash sweeps. While a small convertible loan provides temporary relief, it comes with a high interest rate and strict usage limitations, primarily to seek further financing. The future remains highly uncertain and contingent on securing substantial additional capital, with a high risk of resumed foreclosure.

Positives

• Secured a convertible loan of up to $375,000, providing immediate, albeit limited, liquidity.
• Oxford Finance LLC paused its foreclosure efforts and released $125,000 for critical operational activities.
• The loan allows the Company to prepare and file its Quarterly Report on Form 10-Q, maintaining regulatory compliance.
• The Company is actively exploring strategic options, including potential M&A, licensing, or further financing.

Negatives

• The Company is in severe financial distress, evidenced by Oxford Finance LLC's prior intent to foreclose and sweeping of cash resources.
• The $375,000 loan is a short-term measure with a high 15% annual interest rate, indicating high risk.
• The use of loan proceeds is highly restricted, primarily for seeking additional financing and regulatory filing, not for core operations or R&D (unless further funding is secured).
• The Company is under an exclusivity period until November 17, 2025, limiting its ability to seek other immediate financing options.
• There is no assurance that the exploration of strategic options or additional financing will be successful, or on favorable terms.
• Failure to secure additional financing will likely lead to Oxford Finance LLC resuming foreclosure on the Company's assets.

Risks

• Ability to continue operating as a going concern.
• Uncertainty regarding the outcome and timing of the Oxford Finance LLC foreclosure process.
• Risk of not successfully consummating the First and Second Closings of the convertible loan.
• Inability to negotiate and secure additional financing from the current Lender or another third party.
• Failure to identify and consummate a strategic transaction (e.g., sale, license, merger).
• The Company's financial condition and liquidity may not be sufficient to meet its obligations.
• Potential for dilution if the convertible loan is converted into common stock.

Future Outlook

The Company plans to file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, and continue complying with SEC filing obligations. Subject to securing an additional financing transaction, KALA BIO intends to resume exploring strategic options, which may include a sale, license, merger, or other monetization of remaining assets, seeking further financing, or potentially resuming research and development activities if additional funding becomes available. However, there is no assurance that any such transaction or financing will be completed or on favorable terms. If additional financing is not secured before the current loan proceeds are utilized, Oxford Finance LLC is expected to resume foreclosure efforts on the Company's assets.

Management Comments

• "The Company is only permitted to use the proceeds of the Loan Agreement for the sole purposes of facilitating the negotiation and finalization of an additional investment transaction with the Lender and for preparing and filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025."
• "Subject to consummation of an additional financing transaction with Lender or another third-party, the Company plans to file its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, continue to comply with its filing obligations under the Securities Exchange Act of 1934, as amended, and resume its exploration of strategic options..."
• "There can be no assurance that such exploration of strategic options will result in the Company pursuing a transaction or obtaining additional financing or that any such transaction or financing will be completed, nor as to the terms on which any such transaction or financing will occur, if at all."
• "If the Company does not enter into any such transaction or financing prior to the utilization of the proceeds of the Loan Agreement, the Company expects that Oxford will resume its efforts to foreclose on the Companys assets."

Industry Context

This announcement reflects a common challenge for small biotechnology companies, particularly those without a robust revenue stream or late-stage pipeline, in securing ongoing financing. The high interest rate on the convertible loan and the prior foreclosure actions by Oxford Finance LLC indicate significant financial distress, a situation often seen in the highly capital-intensive and risk-prone biotech sector where R&D success is uncertain and funding is critical for survival. The pursuit of strategic options like sale or merger is typical for companies facing such liquidity constraints, aiming to either find a buyer for their assets or merge to gain access to capital or a stronger pipeline.

Comparison to Industry Standards

• The 15% annual interest rate on the convertible loan is significantly higher than typical corporate debt for financially stable companies, reflecting the high-risk profile of KALA BIO. Established biotech firms with approved products might secure debt financing at single-digit interest rates, while distressed companies often face rates in the high teens or higher, if they can secure financing at all.
• The strict limitations on the use of loan proceeds (only for seeking additional financing and regulatory compliance) are not standard for healthy companies, which typically use funds for R&D, commercialization, or general corporate purposes. This indicates a critical, short-term bridge financing scenario.
• The prior foreclosure actions by Oxford Finance LLC are a severe indicator of financial distress, far outside the norm for a publicly traded company. This situation is comparable to other biotech companies that have faced delisting or bankruptcy due to failed clinical trials or inability to secure follow-on funding, such as Achaogen or Sesen Bio in their final stages.
• The company's stated plan to explore strategic options (sale, license, merger) is a common strategy for struggling biotech firms, similar to what companies like Sorrento Therapeutics or CytoDyn have pursued when facing financial difficulties and needing to monetize assets or find a larger partner.

Stakeholder Impact

• Shareholders: Significant risk of dilution if the convertible loan is converted; high uncertainty regarding the Company's ability to continue as a going concern, potentially leading to substantial loss of investment value.
• Employees: Uncertainty regarding job security due to the Company's precarious financial position and reliance on future financing.
• Creditors (Oxford Finance LLC): Their ability to recover their full loan amount remains uncertain, contingent on KALA BIO's ability to secure further financing or the outcome of potential foreclosure.
• Customers/Partners: Potential impact on future product development or availability if R&D is not resumed or if strategic options do not materialize.

Next Steps

• Receive the first tranche of $187,500 of the loan principal by November 10, 2025.
• Receive the second tranche of $187,500 of the loan principal by November 12, 2025.
• Pay monthly interest on the loan, starting by December 15, 2025.
• Negotiate and finalize an additional investment transaction with the current Lender.
• Prepare and file the Quarterly Report on Form 10-Q for the period ended September 30, 2025.
• Explore strategic options, which may include a sale, license, merger, or other monetization of remaining assets.
• Seek additional financing from other third parties.
• Potentially resume research and development activities, subject to the availability of additional funding.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a prior lender's intent to foreclose and sweep cash. While a small, high-interest convertible loan provides temporary liquidity, its purpose is primarily to seek further financing, not to fund core operations or R&D. The company's ability to continue as a going concern is highly uncertain and contingent on securing substantial additional capital, with a high risk of resumed foreclosure. This situation presents an extremely high risk for investors, suggesting a strong sell recommendation due to the significant likelihood of further value erosion or potential bankruptcy.

Keywords

KALA BIO, Convertible Loan, SEC 8-K, Financial Distress, Foreclosure, Oxford Finance LLC, Strategic Options, Liquidity Event, Nasdaq Capital Market, Biotechnology, Financing, Debt, Equity Conversion